Industry Growth Insights published a new data on “Hereditary Cancer Testing Market”. The research report is titled “Hereditary Cancer Testing Market research by Types (RNA Testing, DNA Testing), By Applications (Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other Cancers), By Players/Companies Ambry Genetics (Konica Minota), Asper Biogene, Natera, Caris Life Sciences, BioReference Laboratories (GeneDx), LabSolutions, Progenity?Inc, ARUP Laboratories, NeoGenomics, Blueprint Genetics, CellMax Life, Fulgent Genetics, Myriad Genetics, Myogenes, LabCorp, Quest Diagnostics, Pathway Genomics, Strand Life Sciences”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hereditary Cancer Testing Market Research Report
By Type
RNA Testing, DNA Testing
By Application
Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other Cancers
By Companies
Ambry Genetics (Konica Minota), Asper Biogene, Natera, Caris Life Sciences, BioReference Laboratories (GeneDx), LabSolutions, Progenity?Inc, ARUP Laboratories, NeoGenomics, Blueprint Genetics, CellMax Life, Fulgent Genetics, Myriad Genetics, Myogenes, LabCorp, Quest Diagnostics, Pathway Genomics, Strand Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Hereditary Cancer Testing Market Report Segments:
The global Hereditary Cancer Testing market is segmented on the basis of:
Types
RNA Testing, DNA Testing
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other Cancers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ambry Genetics (Konica Minota)
- Asper Biogene
- Natera
- Caris Life Sciences
- BioReference Laboratories (GeneDx)
- LabSolutions
- Progenity?Inc
- ARUP Laboratories
- NeoGenomics
- Blueprint Genetics
- CellMax Life
- Fulgent Genetics
- Myriad Genetics
- Myogenes
- LabCorp
- Quest Diagnostics
- Pathway Genomics
- Strand Life Sciences
Highlights of The Hereditary Cancer Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RNA Testing
- DNA Testing
- By Application:
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Other Cancers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hereditary Cancer Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hereditary cancer testing is a process that can be used to identify mutations in the genes that are associated with hereditary cancer. These mutations can lead to the development of this type of cancer.
Some of the key players operating in the hereditary cancer testing market are Ambry Genetics (Konica Minota), Asper Biogene, Natera, Caris Life Sciences, BioReference Laboratories (GeneDx), LabSolutions, Progenity?Inc, ARUP Laboratories, NeoGenomics, Blueprint Genetics, CellMax Life, Fulgent Genetics, Myriad Genetics, Myogenes, LabCorp, Quest Diagnostics, Pathway Genomics, Strand Life Sciences.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hereditary Cancer Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hereditary Cancer Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hereditary Cancer Testing Market - Supply Chain
4.5. Global Hereditary Cancer Testing Market Forecast
4.5.1. Hereditary Cancer Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hereditary Cancer Testing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hereditary Cancer Testing Market Absolute $ Opportunity
5. Global Hereditary Cancer Testing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hereditary Cancer Testing Market Size and Volume Forecast by Type
5.3.1. RNA Testing
5.3.2. DNA Testing
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hereditary Cancer Testing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hereditary Cancer Testing Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Gastrointestinal Cancer
6.3.3. Prostate Cancer
6.3.4. Respiratory/Lung Cancer
6.3.5. Other Cancers
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hereditary Cancer Testing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hereditary Cancer Testing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hereditary Cancer Testing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hereditary Cancer Testing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hereditary Cancer Testing Demand Share Forecast, 2019-2026
9. North America Hereditary Cancer Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hereditary Cancer Testing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hereditary Cancer Testing Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Gastrointestinal Cancer
9.4.3. Prostate Cancer
9.4.4. Respiratory/Lung Cancer
9.4.5. Other Cancers
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hereditary Cancer Testing Market Size and Volume Forecast by Type
9.7.1. RNA Testing
9.7.2. DNA Testing
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hereditary Cancer Testing Demand Share Forecast, 2019-2026
10. Latin America Hereditary Cancer Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hereditary Cancer Testing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hereditary Cancer Testing Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Gastrointestinal Cancer
10.4.3. Prostate Cancer
10.4.4. Respiratory/Lung Cancer
10.4.5. Other Cancers
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hereditary Cancer Testing Market Size and Volume Forecast by Type
10.7.1. RNA Testing
10.7.2. DNA Testing
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hereditary Cancer Testing Demand Share Forecast, 2019-2026
11. Europe Hereditary Cancer Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hereditary Cancer Testing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hereditary Cancer Testing Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Gastrointestinal Cancer
11.4.3. Prostate Cancer
11.4.4. Respiratory/Lung Cancer
11.4.5. Other Cancers
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hereditary Cancer Testing Market Size and Volume Forecast by Type
11.7.1. RNA Testing
11.7.2. DNA Testing
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hereditary Cancer Testing Demand Share, 2019-2026
12. Asia Pacific Hereditary Cancer Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hereditary Cancer Testing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hereditary Cancer Testing Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Gastrointestinal Cancer
12.4.3. Prostate Cancer
12.4.4. Respiratory/Lung Cancer
12.4.5. Other Cancers
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hereditary Cancer Testing Market Size and Volume Forecast by Type
12.7.1. RNA Testing
12.7.2. DNA Testing
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hereditary Cancer Testing Demand Share, 2019-2026
13. Middle East & Africa Hereditary Cancer Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hereditary Cancer Testing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hereditary Cancer Testing Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Gastrointestinal Cancer
13.4.3. Prostate Cancer
13.4.4. Respiratory/Lung Cancer
13.4.5. Other Cancers
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hereditary Cancer Testing Market Size and Volume Forecast by Type
13.7.1. RNA Testing
13.7.2. DNA Testing
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hereditary Cancer Testing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hereditary Cancer Testing Market: Market Share Analysis
14.2. Hereditary Cancer Testing Distributors and Customers
14.3. Hereditary Cancer Testing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Ambry Genetics (Konica Minota)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Asper Biogene
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Natera
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Caris Life Sciences
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. BioReference Laboratories (GeneDx)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. LabSolutions
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Progenity?Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ARUP Laboratories
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. NeoGenomics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Blueprint Genetics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. CellMax Life
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Fulgent Genetics
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Myriad Genetics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Myogenes
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. LabCorp
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Quest Diagnostics
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Pathway Genomics
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Strand Life Sciences
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
